News >

Personalized Medicine Continues to Evolve in Oncology

Caroline Seymour
Published: Monday, Aug 20, 2018

Leonid Shunyakov, MD

Leonid Shunyakov, MD

The use of next-generation sequencing (NGS) is a novel means of improving cancer care, but there are other methods of improving care that extend beyond the panel itself, explained Leonid Shunyakov, MD, a hematologist/oncologist at Central Care Cancer Center.

on A Summer of Progress: Updates from ASCO 2018, Shunyakov discussed the impact genomics has on personalized therapy and the roster of available therapies that continues to grow as a result of identifiable genomic drivers.

OncLive®: How do genomics impact personalized therapy in oncology?

Shunyakov: Genomics is a huge subject. It’s important because we all use genomics in our practice. There are limitations to NGS. There is significant discordance between different assays. FoundationOne and Guardant360 are the 2 most commonly used assays in our practice, but they don’t really match up. The discordance rate is about 70% and the concordance rate is about 20% to 25%. That’s one of the problems with using NGS. The second issue is how to use NGS in novel ways. We used to use NGS to guide our therapy [decisions in a patient with a] single driver mutation, but most cancers are much more complex and have more than one driver.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication